8-K: Aura Biosciences Reports Positive Clinical Data and Third Quarter 2024 Financial Results

Aura Biosciences announced positive Phase 2 data for bel-sar in early-stage choroidal melanoma and promising Phase 1 results in non-muscle invasive bladder cancer, alongside its Q3 2024 financial results.

Summary

• Aura Biosciences reported its financial results for the third quarter of 2024, ending September 30, 2024.
• The company highlighted positive Phase 2 end-of-study data for bel-sar in early-stage choroidal melanoma, showing an 80% tumor control rate and 90% visual acuity preservation.
• Aura also reported positive early data from a Phase 1 trial of bel-sar in non-muscle invasive bladder cancer (NMIBC), with clinical complete responses observed in 4 out of 5 patients with low-grade disease.
• The company's cash position is expected to fund operations into the second half of 2026.
• Research and development expenses increased to $17.0 million for the quarter, up from $15.4 million in the same period last year.
• General and administrative expenses rose to $6.2 million, compared to $5.1 million in the prior year's quarter.
• The net loss for the quarter was $21.0 million, compared to a net loss of $18.5 million for the same period in 2023.
• As of September 30, 2024, the company had $174.4 million in cash, cash equivalents, and marketable securities.
• The Phase 3 CoMpass trial for choroidal melanoma has received authorization to start enrolling patients in Europe, although this was delayed due to additional testing requirements.
• Over 100 patients have been pre-screened globally for the Phase 3 trial since June 2024.

Sentiment

Score: 8

Explanation: The document presents very positive clinical data and a strong cash position, indicating a positive outlook for the company. The delays in European authorization are a minor concern, but the overall tone is optimistic.

Positives

• The Phase 2 results for bel-sar in choroidal melanoma showed a high tumor control rate and visual acuity preservation.
• Early Phase 1 data in NMIBC demonstrated promising clinical complete responses with a single low dose of bel-sar.
• Bel-sar has shown a favorable safety profile in both choroidal melanoma and NMIBC trials, with no serious adverse events reported.
• The company's cash runway extends into the second half of 2026, providing financial stability.
• The Phase 3 CoMpass trial has received authorization to begin enrolling patients in Europe.
• The company is expanding the development of bel-sar into new indications, including metastases to the choroid and cancers of the ocular surface.

Negatives

• The European authorization for the Phase 3 CoMpass trial was delayed due to a requirement for additional testing.
• The company reported a net loss of $21.0 million for the third quarter of 2024, an increase from $18.5 million in the same period of 2023.
• Research and development expenses increased to $17.0 million for the quarter, up from $15.4 million in the same period last year.
• General and administrative expenses rose to $6.2 million, compared to $5.1 million in the prior year's quarter.

Risks

• The company's forward-looking statements are subject to risks and uncertainties, including those related to clinical trials, regulatory approvals, and funding.
• There is a risk that the results of preclinical and clinical trials may not be predictive of future results.
• The company's cash resources may not be sufficient to fund all foreseeable and unforeseeable operating expenses and capital expenditure requirements.
• There is a risk that governmental authorities may disagree with the company's clinical trial designs.
• The company may not receive regulatory approvals to conduct trials or to market products.

Future Outlook

The company expects its current cash position to fund operations into the second half of 2026 and anticipates multiple clinical data readouts in 2025, including Phase 1b/2 expansion data in NMIBC and initial Phase 2 data in metastases to the choroid.

Management Comments

• Elisabet de los Pinos, PhD, Chief Executive Officer of Aura Biosciences, stated that the positive data in NMIBC provides clinical evidence of the potential of bel-sar in solid tumors beyond the eye.
• Carol L. Shields, MD, Chief of the Ocular Oncology Service at Wills Eye Hospital, expressed excitement for bel-sar's potential for patients with indeterminate lesions or small choroidal melanoma.

Industry Context

Aura Biosciences is developing bel-sar, a novel virus-like drug conjugate, which represents a new class of drugs with a dual mechanism of action targeting tumor cells and activating the immune system. This approach is relevant in the context of the growing need for effective and less invasive treatments for solid tumors, particularly in areas with high unmet needs such as choroidal melanoma and bladder cancer. The company's focus on preserving organ function aligns with a broader trend in oncology towards more targeted and less toxic therapies.

Comparison to Industry Standards

• The 80% tumor control rate in the Phase 2 choroidal melanoma study is a strong result compared to traditional treatments like radiation, which often lead to vision loss.
• The 90% visual acuity preservation rate is also notable, as current treatments for choroidal melanoma often result in significant vision impairment.
• The early complete response rate in low-grade NMIBC patients is promising, especially given the high recurrence rates associated with current treatments like TURBT and BCG.
• The favorable safety profile of bel-sar in both choroidal melanoma and NMIBC trials is a positive differentiator compared to other cancer therapies that often have significant side effects.
• The company's focus on local administration of bel-sar in the urology clinic aligns with current practices and could reduce the treatment burden for patients.

Management Changes

Stakeholder Impact

• Shareholders are likely to react positively to the strong clinical data and cash position.
• Patients with choroidal melanoma and NMIBC may benefit from the development of bel-sar as a new treatment option.
• Employees may be positively impacted by the company's growth and progress.
• The company's strategic collaborators may be encouraged by the positive results and continued development of bel-sar.

Next Steps

• The company plans to continue development of bel-sar in bladder cancer with an initial focus on low-grade, intermediate risk NMIBC patients.
• Aura Biosciences is planning regulatory discussions on the design of the next trial for bel-sar in bladder cancer.
• The company aims to enroll the first patients in a Phase 2 trial for metastases to the choroid in 2024.
• The company continues to advance its preclinical work designed to be IND-enabling in cancers of the ocular surface.
• The company expects multiple clinical data readouts in 2025, including Phase 1b/2 expansion data in NMIBC and initial Phase 2 data in metastases to the choroid.

Key Dates

Keywords

bel-sar, choroidal melanoma, bladder cancer, NMIBC, ocular oncology, clinical trial, Phase 3, Phase 2, Phase 1, biotechnology, cancer therapy, tumor control, visual acuity, immune activation